

# Filippo Canducci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5094632/publications.pdf>

Version: 2024-02-01

53  
papers

2,482  
citations

218592

26  
h-index

206029

48  
g-index

53  
all docs

53  
docs citations

53  
times ranked

4374  
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of gut barrier integrity triggers activation of islet-reactive T cells and autoimmune diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15140-15149.	3.3	134
2	Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nature Communications, 2018, 9, 4832.	5.8	144
3	Testicular microbiome in azoospermic men—first evidence of the impact of an altered microenvironment. Human Reproduction, 2018, 33, 1212-1217.	0.4	83
4	Increased iNKT17 Cell Frequency in the Intestine of Non-Obese Diabetic Mice Correlates With High Bacteroidales and Low Clostridiales Abundance. Frontiers in Immunology, 2018, 9, 1752.	2.2	8
5	Prenylated phloroglucinols from <i>Hypericum scruglii</i> , an endemic species of Sardinia (Italy), as new dual HIV-1 inhibitors effective on HIV-1 replication. PLoS ONE, 2018, 13, e0195168.	1.1	34
6	Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides. PLoS ONE, 2018, 13, e0198478.	1.1	25
7	The Microbiome of the Prostate Tumor Microenvironment. European Urology, 2017, 72, 625-631.	0.9	154
8	Natural Product Kuwanon $\epsilon$ Inhibits HIV $\epsilon$ 1 Replication through Multiple Target Binding. ChemBioChem, 2017, 18, 374-377.	1.3	27
9	High frequency of intestinal T <sub>H</sub> 17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Science Advances, 2017, 3, e1700492.	4.7	228
10	IL28B rs12979860 genotype as a predictor marker of progression to BKVirus Associated nephropathy, after kidney transplantation. Scientific Reports, 2017, 7, 6746.	1.6	4
11	Revealing enterovirus infection in chronic human disorders: An integrated diagnostic approach. Scientific Reports, 2017, 7, 5013.	1.6	28
12	One drug for two targets: Biological evaluation of antiretroviral agents endowed with antiproliferative activity. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2502-2505.	1.0	8
13	Oral Probiotic VSL#3 Prevents Autoimmune Diabetes by Modulating Microbiota and Promoting Indoleamine 2,3-Dioxygenase-Enriched Tolerogenic Intestinal Environment. Journal of Diabetes Research, 2016, 2016, 1-12.	1.0	111
14	Adaptive immunity against gut microbiota enhances apoE-mediated immune regulation and reduces atherosclerosis and western-diet-related inflammation. Scientific Reports, 2016, 6, 29353.	1.6	28
15	Inhibition of HIV $\epsilon$ 1 Reverse Transcriptase Dimerization by Small Molecules. ChemBioChem, 2016, 17, 683-688.	1.3	15
16	The interplay of extracellular matrix and microbiome in urothelial bladder cancer. Nature Reviews Urology, 2016, 13, 77-90.	1.9	89
17	Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the <i>N</i> -Dihydroalkyloxybenzyloxypyrimidines (N-DABOs) Family. Journal of Medicinal Chemistry, 2016, 59, 2747-2759.	2.9	22
18	Kuwanon $\epsilon$ as a New Allosteric HIV $\epsilon$ 1 Integrase Inhibitor: Molecular Modeling and Biological Evaluation. ChemBioChem, 2015, 16, 2507-2512.	1.3	39

#	ARTICLE	IF	CITATIONS
19	Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1391-1395.	1.3	10
20	2-Aminothiazolones as Anti-HIV Agents That Act as gp120-CD4 Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3043-3052.	1.4	13
21	Immunological Recovery After 24 Weeks of Antiretroviral Therapy in Patients With X4 Virus During Primary HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, e27-e29.	0.9	3
22	Infection and Coinfection of Human Rhinovirus C in Stem Cell Transplant Recipients. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-5.	3.3	4
23	In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2525-2532.	1.3	27
24	Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1224-1227.	1.3	14
25	Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 213-217.	1.3	26
26	Epidemiological, molecular and clinical features of Enterovirus 109 infection in children and in adult stem cell transplant recipients. <i>Virology Journal</i> , 2012, 9, 183.	1.4	6
27	The role of infections and coinfections with newly identified and emerging respiratory viruses in children. <i>Virology Journal</i> , 2012, 9, 247.	1.4	97
28	Cross-Reacting Antibacterial Auto-Antibodies Are Produced within Coronary Atherosclerotic Plaques of Acute Coronary Syndrome Patients. <i>PLoS ONE</i> , 2012, 7, e42283.	1.1	17
29	The new and less toxic protease inhibitor saquinavirâ€™NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir. <i>Antiviral Research</i> , 2011, 91, 292-295.	1.9	9
30	Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir. <i>Journal of Infectious Diseases</i> , 2011, 204, 1811-1815.	1.9	94
31	Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients With Recent Diagnosis of HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e51-e53.	0.9	14
32	Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. <i>Aids</i> , 2010, 24, 924-928.	1.0	43
33	Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). <i>Virology</i> , 2010, 399, 144-152.	1.1	40
34	Molecular epidemiology of KI and WU polyomaviruses in infants with acute respiratory disease and in adult hematopoietic stem cell transplant recipients. <i>Journal of Medical Virology</i> , 2010, 82, 153-156.	2.5	30
35	Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 425-433.	1.3	53
36	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. <i>New Microbiologica</i> , 2010, 33, 195-206.	0.1	35

#	ARTICLE	IF	CITATIONS
37	Antigen-Driven Evolution of B Lymphocytes in Coronary Atherosclerotic Plaques. <i>Journal of Immunology</i> , 2009, 183, 2537-2544.	0.4	27
38	Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. <i>Retrovirology</i> , 2009, 6, 4.	0.9	18
39	Pregnancy and H1N1 infection. <i>Lancet, The</i> , 2009, 374, 1417.	6.3	13
40	Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. <i>Aids</i> , 2009, 23, 455-460.	1.0	66
41	Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). <i>New Microbiologica</i> , 2009, 32, 319-24.	0.1	22
42	Two-year prospective study of single infections and co-infections by respiratory syncytial virus and viruses identified recently in infants with acute respiratory disease. <i>Journal of Medical Virology</i> , 2008, 80, 716-723.	2.5	144
43	Persistent Replication of Severe Acute Respiratory Syndrome Coronavirus in Human Tubular Kidney Cells Selects for Adaptive Mutations in the Membrane Protein. <i>Journal of Virology</i> , 2008, 82, 5137-5144.	1.5	50
44	Anti-HIV-1 Response Elicited in Rabbits by Anti-Idiotypic Monoclonal Antibodies Mimicking the CD4-Binding Site. <i>PLoS ONE</i> , 2008, 3, e3423.	1.1	21
45	Long-term study on symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. <i>New Microbiologica</i> , 2007, 30, 255-8.	0.1	17
46	Quantitation of <i>Bacillus clausii</i> in biological samples by real-time polymerase chain reaction. <i>Journal of Microbiological Methods</i> , 2006, 65, 632-636.	0.7	5
47	Cloning and molecular characterization of a human recombinant IgG Fab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient. <i>Molecular Immunology</i> , 2006, 43, 1363-1369.	1.0	4
48	Use of Genotype MTBDR Assay for Molecular Detection of Rifampin and Isoniazid Resistance in <i>Mycobacterium tuberculosis</i> Clinical Strains Isolated in Italy. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2485-2491.	1.8	98
49	Persistent Symptomless Human Metapneumovirus Infection in Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2006, 194, 474-478.	1.9	89
50	<i>Coronaviridae</i> and SARS-associated Coronavirus Strain HSR1. <i>Emerging Infectious Diseases</i> , 2004, 10, 413-418.	2.0	127
51	Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. <i>Virology</i> , 2004, 327, 242-248.	1.1	28
52	Evolutionary Characteristics of HIV Type 1 Variants Resistant to Protease Inhibitors in the Absence of Drug-Selective Pressure. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1151-1153.	0.5	16
53	<i>Helicobacter pylori</i> Treatment: A Role for Probiotics?. <i>Digestive Diseases</i> , 2001, 19, 144-147.	0.8	21